The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15. The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial.

Carl D. Regillo, MD, FACS, reviews long-term efficacy and safety findings from the Port Delivery System clinical trial program. Seven years of follow-up data from the Port Delivery System (PDS) ...

From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua Mali, MD, FASRS, shares what he believes will define ophthalmology in the ...

SOL-1 data show OTX-TKI extends rescue-free control in treatment-naive wet AMD, shaping AI-driven trial design and longer-interval care. Barakat opened by highlighting what makes CTS uniquely valuable ...

The trial is expected to close randomization in early December 2024. More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The ...

Voretigene neparvovec (Luxturna, Spark Therapeutics, Inc.) was shown to be safe and effective in real-world settings. The 3-year interim results of the PERCEIVE Study, a large international trial, ...

The International Retinal Imaging Society (IntRIS) had a significant presence at this year's EURETINA Congress. Marion Munk, a medical retina and uveitis specialist from Switzerland, introduced the ...

Catch up on recent advancements in retina care, including new therapies for age-related macular degeneration and macular telangiectasia, enhancing patient outcomes. Now is an exciting time to be a ...

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD. EyePoint Pharmaceuticals recently announced the completion of ...

A panelist discusses how interpreting clinical trial data, monitoring disease progression, and maintaining transparent communication help retina specialists make informed decisions about when and how ...